

ABSTRACT OF THE DISCLOSURE

A novel use of platelet-activating factor antagonists that bind to intracellular PAF binding sites such as BN-50730 (tetrahydro-4,7,8,10-methyl-1-(chloro-1-phenyl)-6-(methoxy-4-phenyl-carbamoyl)-9-pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4) has
5 been discovered. These intracellular-binding platelet-activating factor antagonists were found to inhibit both *in vivo* and *in vitro* tumor growth and angiogenesis where the angiogenesis is stimulated by basic fibroblast growth factor.